Vitamin D receptor expression is linked to potential markers of human thyroid papillary carcinoma

2016 ◽  
Vol 159 ◽  
pp. 26-30 ◽  
Author(s):  
Elena Izkhakov ◽  
Dalia Somjen ◽  
Orli Sharon ◽  
Esther Knoll ◽  
Asaf Aizic ◽  
...  
Keyword(s):  
Vitamin D ◽  
Papillary Carcinoma ◽  
Vitamin D Receptor ◽  
Receptor Expression ◽  
Thyroid Papillary Carcinoma ◽  
Human Thyroid ◽  
Thyroid Papillary

Protein Tyrosine Kinase Activity in Human Thyroid Papillary Carcinoma

1992 ◽  
Vol 31 (4) ◽  
pp. 409-412 ◽  
Author(s):  
Yoshiyuki Yasuda ◽  
Youichirou Sakanoue ◽  
Takuya Hatada ◽  
Toru Nakai ◽  
Joji Utsunomiya
Keyword(s):  
Tyrosine Kinase ◽  
Papillary Carcinoma ◽  
Protein Tyrosine Kinase ◽  
Kinase Activity ◽  
Thyroid Papillary Carcinoma ◽  
Human Thyroid ◽  
Tyrosine Kinase Activity ◽  
Protein Tyrosine ◽  
Thyroid Papillary ◽  
Protein Tyrosine Kinase Activity

scholarly journals RFLP for TaqI of the human thyroid papillary carcinoma (PTC) oncogene

1988 ◽  
Vol 16 (18) ◽  
pp. 9062-9062 ◽  
Author(s):  
P. Radice ◽  
R. Donghi ◽  
M. A. Pierotti ◽  
A. Longoni ◽  
A. Fusco ◽  
...  
Keyword(s):  
Papillary Carcinoma ◽  
Thyroid Papillary Carcinoma ◽  
Human Thyroid ◽  
Thyroid Papillary

Characterization of a novel rearrangement from the ret/PTC family in a case of radiation-associated human thyroid papillary carcinoma

2003 ◽  
Vol 1258 ◽  
pp. 141-146
Author(s):  
Vladimir A. Saenko ◽  
Tatiana I. Rogounovitch ◽  
Yuki Shimizu-Yoshida ◽  
Aleksandr Yu. Abrosimov ◽  
Eugeny F. Lushnikov ◽  
...  
Keyword(s):  
Papillary Carcinoma ◽  
Thyroid Papillary Carcinoma ◽  
Human Thyroid ◽  
Thyroid Papillary

In vitro antitumoral effects of the steroid ouabain on human thyroid papillary carcinoma cell lines

2021 ◽  
Author(s):  
Mariana Pires Teixeira ◽  
Eliza Freitas Passos ◽  
Natalia Ferreira Haddad ◽  
Marcelle Novaes Andrade ◽  
Vivian Mary Rumjanek ◽  
...  
Keyword(s):  
Papillary Carcinoma ◽  
Cell Lines ◽  
Carcinoma Cell ◽  
Thyroid Papillary Carcinoma ◽  
Human Thyroid ◽  
Carcinoma Cell Lines ◽  
Thyroid Papillary

Alpha1-Antitrypsin Expression in Human Thyroid Papillary Carcinoma

1996 ◽  
Vol 20 (8) ◽  
pp. 956-963 ◽  
Author(s):  
Maria T. Poblete ◽  
Francisco Nualart ◽  
Maeva del Pozo ◽  
Juan A. Perez ◽  
Carlos D. Figueroa
Keyword(s):  
Papillary Carcinoma ◽  
Thyroid Papillary Carcinoma ◽  
Human Thyroid ◽  
Thyroid Papillary ◽  
Alpha1 Antitrypsin

scholarly journals Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAFV600E mutation treated with dabrafenib–trametinib: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
M. C. Martín-Soberón ◽  
S. Ruiz ◽  
G. De Velasco ◽  
R. Yarza ◽  
A. Carretero ◽  
...  
Keyword(s):  
Case Report ◽  
Papillary Carcinoma ◽  
Radioactive Iodine ◽  
Specific Treatment ◽  
Pneumatosis Intestinalis ◽  
Thyroid Papillary Carcinoma ◽  
Intestinal Pneumatosis ◽  
Abdominal Symptoms ◽  
Positron Emission ◽  
Thyroid Papillary

Abstract Background Pneumatosis intestinalis (PI) is a rare entity which refers to the presence of gas within the wall of the small bowel or colon which is a radiographic sign. The etiology and clinical presentation are variable. Patients with PI may present either with chronic mild non-specific symptoms or with acute abdominal pain with peritonitis. Some cases of intestinal pneumatosis have been reported as adverse events of new oncological treatments such as targeted therapies that are widely used in multiple tumors. Case presentation A 59-year-old caucasian female with radioactive iodine-refractory metastatic thyroid papillary carcinoma with BRAFV600E mutation was treated with dabrafenib and trametinib as a compassionate use. After 4 months treatment, positron emission tomography–computed tomography (PET–CT) showed PI. At the time of diagnosis, the patient was asymptomatic without signs of peritonitis. The initial treatment was conservative and no specific treatment for PI was needed. Unfortunately, after dabrafenib–trametinib withdrawal, the patient developed tumor progression with significant clinical worsening. Conclusions This case report is, in our knowledge, the first description of PI in a patient treated with dabrafenib–trametinib. Conservative treatment is feasible if there are no abdominal symptoms.

Sign in / Sign up

Export Citation Format

Share Document